HIFU Reapplication in Benign Nodules
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03331172|
Recruitment Status : Completed
First Posted : November 6, 2017
Last Update Posted : October 11, 2018
High Intensity Focused Ultrasound (HIFU) is a new approach in treating benign thyroid nodule without surgery. It is proven effective and safe relative to traditional surgery. From previous HIFU studies, it caused shrinkage of thyroid nodule up to 70% from original size. Unfortunately, 5-10% of nodule do not shrink. Those which do not shrink are usually large in size and therefore a second HIFU treatment may help. This study is going to evaluate the efficacy and safety of reapplication HIFU after the first single HIFU session in 6 months.
The study will be carried out in the following steps:
- Recruit subject from the clinic according to the study criteria.
- Arrange the reapplication HIFU treatment within 3 months.
- Arrange 4 visits after the HIFU treatment in Post 7 days, Post 1 month, Post 3 months, and Post 6 months; Data collection will be in these 4 visits through the questionnaire or interview by research assistant
- The subjects will have further health management with the same team after the study.
|Condition or disease||Intervention/treatment||Phase|
|Thyroid Nodule||Device: Echopulse||Not Applicable|
Thyroid nodules are common and although most are benign and remain relatively static in size, some can grow and become large and cause local symptoms over time. In such scenario, thyroidectomy is usually indicated. However, surgery is not only associated with complications but also with high cost and general anesthesia. As a result, there has been a growing interest in exploring less invasive, non-surgical technique for benign thyroid nodules. For solid or predominantly-solid (<30% cystic areas) thyroid nodules, thermal ablation techniques have been shown to be highly effective in causing nodule shrinkage and alleviating symptoms in the long-term. To date, numerous thermal ablation techniques have been described and they include radiofrequency ablation (RFA), percutaneous laser ablation (PLA), microwave ablation and more recently, high intensity focused ultrasound (HIFU). HIFU is now considered the least invasive technique as there is no need for needle insertion into the target lesion during treatment. It works by utilizing focused ultrasound energy to generate heat and induce thermal ablation beneath the skin and other tissue layers. Recent studies (including several from our group) have shown that it is effective in not only inducing significant nodule shrinkage but also in alleviating nodule-related symptoms.
However, despite its overall success, approximately 10 - 15% of solid or predominantly solid nodules do not shrink adequately (i.e. <50% shrinkage from baseline in the first 6-12 months). Although the exact reason why some nodules do not respond remains unclear, it is noted that the majority of these less responsive nodules are larger in size / volume and so, a second or reapplication of ablation might be required to cause further shrinkage and improvement in symptoms . However, the role of HIFU reapplication in nodules with less-than-adequate response (<50% at 6 months) remains undefined. As a result, the present study is aimed to the feasibility and safety of HIFU reapplication in nodules with shrinkage <50% of baseline volume 6 months after single-session HIFU treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.|
|Actual Study Start Date :||July 1, 2017|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||August 30, 2018|
|Experimental: High Intensity Focused Ultrasound||
Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
Other Name: High Intensity Focused Ultrasound (HIFU)
- Change in thyroid nodule volume (mL) [ Time Frame: 6 months ]To measure the change in volume (mL) of the index (or treated) thyroid nodule 6 months following HIFU reapplication
- The efficacy of reapplication HIFU after the first single session in 6 months [ Time Frame: 6 months ]To compare the change in volume (mL) of the treated thyroid nodule between the first single session and the reapplication.
- The safety of reapplication HIFU after the first single session in 6 months [ Time Frame: 6 months ]To assess the safety of reapplication HIFU by recording any complications after the treatment
- The rate of vocal cord palsy in reapplication HIFU after the first single session in 6 months [ Time Frame: 6 months ]To examine the rate of vocal cord palsy in reapplication HIFU after the first single session in 6 month
- The cosmetic score (in 0-10) of reapplication HIFU after the first single session in 6 months [ Time Frame: 6 months ]To evaluate the cosmetic score (in 0-10) of reapplication HIFU after the first single session in 6 months
- The pain score (in 0-10) of reapplication HIFU after the first single session in 6 months [ Time Frame: 6 months ]To evaluate the pain score (in 0-10) of reapplication HIFU after the first single session in 6 month
- The satisfactory (in 0-10) of reapplication HIFU after the first single session in 6 month [ Time Frame: 6 months ]The satisfactory level, from scoring in 0-10, to examine how participants' satisfaction in the reapplication HIFU after the first single session in 6 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03331172
|Queen Mary Hospital|
|Hong Kong, Hong Kong|
|Principal Investigator:||Hung Hin, Brian Lang, MBBS (Hons)||The University of Hong Kong|